what was anticipated to be the largest bond offering in history. With considerable ongoing turmoil in world financial markets and substantial uncertainty surrounding the willingness of Genentech minority shareholders to actually sell their shares for the reduced offer USD86.50, Roche’s financing strategy was certainly bold.